Is the DUTCH Test Legitimate? What the Evidence Shows

The DUTCH Test (Dried Urine Test for Comprehensive Hormones) occupies a gray zone: the underlying analytical chemistry is real and peer-reviewed, but the clinical interpretations built on top of it often outrun the evidence. Dried urine can accurately measure many hormones and their breakdown products, and the collection method shows strong agreement with traditional liquid urine and, in some cases, serum measurements. Where things get murkier is in what those measurements mean for individual patients, how they should guide treatment, and whether the sprawling panels of metabolites the test reports actually change health outcomes.

What the DUTCH Test Actually Measures

The test collects urine on filter paper at four or five time points over a 24-hour period, then uses gas chromatography with tandem mass spectrometry (GC-MS/MS) to quantify a long list of analytes. These include cortisol and its metabolites, estrogen metabolites (estradiol, estrone, estriol, and their hydroxylated forms), progesterone metabolites, androgens like testosterone and DHEA, melatonin’s primary urinary metabolite, and a handful of organic acids and nutritional markers. The idea is that by sampling across the day, you capture not just a snapshot but a rough diurnal pattern, especially for cortisol, which rises and falls on a predictable curve.

The dried filter paper method itself is not new or fringe. Dried biological specimens have been used in clinical chemistry for decades, most famously in newborn screening. What Precision Analytical (the company behind the DUTCH Test) did was apply the approach specifically to hormone profiling and package it into a consumer-facing product with detailed interpretive reports.

Does Dried Urine Accurately Capture Hormone Levels?

On the pure measurement side, the evidence is encouraging. A validation study comparing dried urine to conventional liquid urine found excellent agreement for the vast majority of analytes, with intraclass correlation coefficients at or above 0.90 for most hormones. The only exceptions were two markers (VMA and pyroglutamic acid) that still showed good, though not excellent, agreement.¹ For cortisol specifically, comparisons between dried and liquid urine showed near-ideal consistency for free cortisol, cortisone, and total cortisol metabolites.²

A separate study focusing on estrogen and progesterone metabolites found that the four-spot dried urine collection method agreed well with traditional 24-hour urine collections, with intraclass correlations above 0.95. The dried urine metabolite concentrations in a small group of women also followed the same cyclical pattern as their serum hormone concentrations during menstrual cycles.³ So the drying process itself does not meaningfully distort the results. The test measures what it says it measures, at least at the analytical level.

How Well Does Urine Reflect What Is Happening in Your Blood?

This is where the picture starts to get more complicated. Hormones in urine are not the same molecules circulating in your bloodstream; they are metabolites that have already been processed by the liver, kidneys, and gut before being excreted. Whether urinary levels reliably track serum levels depends on the specific hormone and the population being tested.

For estrogens, a large study comparing serum, plasma, and urinary measurements found moderate correlations at best. In postmenopausal women, the strongest correlations between serum and urinary estrogens topped out around 0.76, while many individual estrogen metabolites showed weaker associations. In premenopausal women, the correlations were generally lower still, and in men, results were mixed.⁴ A correlation of 0.5 to 0.7 means there is a real relationship, but a lot of individual variation goes unexplained. In practice, two people with the same serum estradiol could have noticeably different urinary metabolite profiles.

For progesterone, the relationship is better established for tracking patterns over time than for pinpointing absolute levels on a given day. Classic research showed that urinary profiles of progesterone’s main metabolite (pregnanediol glucuronide) paralleled the serum progesterone profile across the menstrual cycle.⁵ But the same work also found that after oral progesterone treatment, urinary metabolite levels were considerably more variable and peaked much later than serum levels, with a lag of four to twelve hours. That time lag matters when trying to interpret a spot measurement as a proxy for what the blood was doing at that moment.

Earlier research using different immunoassay methods confirmed this general finding: urinary steroid metabolite profiles tracked the shape of their parent hormones in serum, even if the absolute numbers did not translate one-to-one.⁶ The takeaway: urinary hormone testing is generally better at showing trends and relative changes than at establishing a precise serum equivalent for any single time point.

Where the Testing Has the Strongest Footing

Certain parts of the DUTCH panel rest on well-established clinical science. Urinary cortisol metabolites have been used in endocrinology for decades to evaluate conditions like Cushing’s syndrome, where total cortisol production is elevated. The DUTCH test extends this by also tracking cortisone and the ratio between the two, giving a picture of how the body is processing cortisol. The multi-point collection adds a rough diurnal curve, which is useful because a single morning cortisol value can be normal even when the overall daily pattern is disrupted.

Estrogen metabolism profiling is another area with legitimate research behind it. The ratio of 2-hydroxyestrone to 16-alpha-hydroxyestrone (often called the 2:16 ratio) has been studied as a potential marker for breast cancer risk. Research found that women at high risk for breast cancer and those already diagnosed had significantly lower 2:16 ratios compared to healthy controls, and this association held after adjusting for age and smoking history.⁷ This does not mean the DUTCH Test can diagnose breast cancer, but it illustrates that estrogen metabolite patterns in urine carry real biological information. The clinical utility as a screening tool, however, is not settled.

Androgen metabolism profiling also has solid backing for specific conditions. In women with polycystic ovary syndrome (PCOS), urinary androgen metabolites are consistently elevated. Research has demonstrated that women with PCOS show significantly higher total urinary androgen metabolites and increased activity of the enzyme 5-alpha-reductase, which converts testosterone into its more potent form.⁸ This pattern held for both obese and non-obese women with the condition, and has been replicated in other work showing that PCOS patients had greater increases in 5-alpha-reduced metabolites after being given DHEA.⁹ Urinary metabolite profiling can reveal downstream enzyme activity that a simple serum testosterone measurement would miss.

Melatonin and Sleep Assessment

The DUTCH Test includes 6-sulfatoxymelatonin (aMT6s), the primary urinary metabolite of melatonin. Research has established that the timing of aMT6s excretion onset correlates with the timing of the steepest increase in nighttime sleepiness.¹⁰ More recent work in a clinical sleep-disorder population found moderate correlations between the peak timing of aMT6s and sleep onset, midpoint, and offset, with stronger associations when people kept fixed schedules.¹¹

A large study in older men found that urinary melatonin levels were inversely associated with daytime sleepiness and, in men not taking beta-blockers (which suppress melatonin), low aMT6s was linked to short sleep duration and worse sleep efficiency.¹² Urinary melatonin measurement is a real research tool, but these correlations are moderate, not definitive. Whether an individual’s aMT6s level translates into actionable treatment guidance is a different question from whether the measurement itself is valid.

Where the Evidence Gets Thin

Some parts of the DUTCH panel stretch further than the published research supports. The test reports on several organic acids, which are real metabolic compounds with established roles. Urinary organic acids do reflect the activity of major metabolic pathways and have clinical applications in detecting certain nutrient deficiencies and metabolic disorders.¹³ Urinary methylmalonic acid, for example, has been validated as a useful marker of vitamin B12 deficiency because it is directly tied to a B12-dependent metabolic pathway.¹⁴

The problem is not that these markers are meaningless but that the clinical interpretations attached to them in DUTCH reports often go beyond what the research supports. A review of the evidence on urinary neurotransmitter testing found some basis for using urinary neurotransmitters as biomarkers of nervous system activity, including historical use in diagnosing a specific adrenal tumor (pheochromocytoma) and correlations with depression, ADHD, and inflammation. But the same review highlighted significant limitations and challenges with the approach.¹³ Measuring a neurotransmitter metabolite in urine and then telling someone their serotonin is “low” represents a leap that the science does not fully support.

What Mainstream Endocrinology Says

The Endocrine Society’s scientific statement on compounded bioidentical hormones is direct on this point: for estrogen, progestin, and DHEA, the practice of baseline hormone measurements to replace “abnormal” hormone deficiencies has no basis in medical practice. The Society also stated there is no evidence that monitoring compounded hormone therapy with serial salivary or blood testing is effective, with the exception of thyroid hormone.¹⁵ Although this statement was directed at salivary and blood testing rather than dried urine specifically, the underlying criticism applies: there is limited evidence that serial hormone level monitoring improves outcomes in most hormone replacement scenarios.

A broader review of laboratory tests commonly used in complementary and alternative medicine concluded that many such tests are of dubious clinical significance, that some have been widely discredited, and that results are often accompanied by extensive interpretations recommending unnecessary or potentially harmful treatments. This was not a review of the DUTCH Test specifically, but it describes the ecosystem in which comprehensive hormone panels are often marketed and used.

That said, there are scenarios where mainstream medicine does value urinary hormone profiling. Twenty-four-hour urinary cortisol is a standard clinical test for Cushing’s syndrome. Urinary catecholamines are standard for investigating pheochromocytoma. And research on dried urine assays for monitoring transdermal estrogen therapy has shown that the method can detect dose-proportional changes in estrogen metabolites, distinguishing between premenopausal women, postmenopausal women on estrogen replacement, and postmenopausal women on no therapy.^{16 17} The analytical capability is there; the debate is about how that capability should be applied clinically.

Practical Concerns That Affect Results

Even when the lab chemistry is solid, real-world factors introduce variability that DUTCH reports do not always adequately convey. Hydration status matters: someone who drinks very little water concentrates their urine, inflating hormone metabolite values, while someone who overhydrates dilutes them. The test uses creatinine to normalize results, but research in adolescents found that urine creatinine itself varies with age, sex, and pubertal stage, and that adjusting by creatinine did not improve correlation with serum concentrations compared to unadjusted values.¹⁸ In adults the correction works reasonably well, but it is not a perfect fix.

Natural biological variability is another factor. Steroid excretion can fluctuate substantially from day to day in the same person. This has been documented especially in conditions involving adrenal dysregulation, where urinary steroid levels varied enough from one day to the next that a single day’s measurement could be misleading.¹⁹ The DUTCH Test’s multi-point sampling over one day helps compared to a single blood draw, but it still represents only 24 hours. For hormones that fluctuate with the menstrual cycle, collection timing matters enormously: the same woman can have dramatically different results depending on whether she collects during the follicular or luteal phase.

For women on progesterone therapy, the timing gap between taking the dose and collecting urine introduces its own ambiguity. Oral progesterone produces a surge in urinary metabolites that peaks hours after the dose and drops substantially by 24 hours, with high variability in the metabolite pregnanediol glucuronide specifically.⁵ When a provider interprets a DUTCH result without accounting for this pharmacokinetic wrinkle, the numbers can be misleading in either direction.

The Gap Between Measurement and Clinical Action

The core tension around the DUTCH Test is not really about whether dried urine can measure hormones accurately. It can, and the validation data support that. The tension is about what happens after the numbers come back. A typical DUTCH report generates pages of results with color-coded ranges and interpretive commentary. For a practitioner trained in functional or integrative medicine, those results may prompt supplement recommendations, dietary changes, or adjustments to hormone prescriptions. The question is whether those interventions are based on clinical evidence or on pattern-matching with reference ranges that have not been validated against health outcomes.

Knowing that your 2:16 estrogen metabolite ratio is low, for instance, is interesting in light of the breast cancer research cited earlier. But no randomized trial has demonstrated that measuring this ratio in an individual woman and then intervening to change it actually reduces her cancer risk. The research shows a population-level association between the ratio and cancer risk, which is not the same thing as showing that the ratio is a useful clinical decision tool for an individual.

Similarly, the DUTCH Test’s cortisol curve can show a flat or inverted pattern, which the report may flag as “adrenal dysfunction.” Mainstream endocrinology does not recognize “adrenal fatigue” as a diagnosis, though it does recognize adrenal insufficiency (Addison’s disease) and Cushing’s syndrome. The urinary cortisol metabolite data from a DUTCH Test could, in principle, prompt further workup for these real conditions, but the interpretive framework many functional medicine practitioners apply goes well beyond what endocrinology societies endorse.

Who Finds It Useful and Why

In practice, the DUTCH Test tends to appeal to two groups. The first is practitioners who want a broader metabolic picture than a standard serum hormone panel provides. For clinicians monitoring transdermal hormone therapy, for example, urinary estrogen metabolite profiling can detect changes that serum estradiol alone might miss, since transdermal estrogen bypasses first-pass liver metabolism and may not raise serum levels as reliably as oral formulations.¹⁷ In this scenario, the test fills a genuine clinical gap.

The second group is health-conscious consumers drawn to the idea of comprehensive testing. The appeal is understandable: a detailed map of your hormonal landscape sounds like it should be more useful than a basic blood panel. And for some people, the results do lead to meaningful conversations with knowledgeable providers and worthwhile changes. The risk is when the same results are interpreted by practitioners without deep endocrinology training, or when the extensive report creates anxiety over values that are within normal biological variation.

Ovulation Confirmation and Fertility Applications

One practical application of urinary progesterone metabolite testing is confirming ovulation. Rather than relying solely on basal body temperature or LH surge detection, some fertility-aware practitioners use pregnanediol glucuronide (PDG) levels to verify that progesterone rose after ovulation. Research evaluating urine PDG test strips found that the threshold matters: strips calibrated at a lower threshold (5 micrograms per milliliter) correctly identified ovulatory cycles about 82% of the time, while a higher threshold caught only 59%.²⁰ The DUTCH Test uses mass spectrometry rather than dipstick immunoassay, so its measurement is considerably more precise. For women trying to confirm that they are ovulating and producing adequate progesterone in the luteal phase, urinary metabolite testing has a clear and defensible use case, though it is not the only way to get this information.

The distinction matters because fertility applications deal with a straightforward biological question (did progesterone rise after ovulation?) rather than the more speculative interpretive frameworks that surround some other parts of the DUTCH panel. When the clinical question is narrow and well-defined, urinary hormone metabolite testing tends to perform well. When the question is vague (“optimize my hormones”), the test generates data that can be hard to act on responsibly.